POS0187 THE PROGNOSTIC FACTORS IN PREDICTING RELAPSE FOR IGG4-RELATED DISEASE: A LONG-TERM STUDY BASED ON THE CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF THE PATIENTS

Background: The relationship between the pathological findings and disease relapse has not been well established. Objectives: We aim to investigate clinical manifestations in relation with IgG4-RD, as identify prognostic factors predicting relapsed disease. Methods: This study enrolled 71 patients newly diagnosed IgG4-RD Jan 2011 April 2020, all of whom had received examinations. Their data were collected. Multivariate Cox regression AUC (area under curve) used predictors for assess predictive value these predictors, respectively. Results: During a follow-up period 26 (range, 6-123) months, 4.2% (3/71) died. remaining 68 treated glucocorticoids or without immunosuppressor continuously. By end follow-up, 47 (69.1%) sustained remission, 21 (30.9%) suffered median time at 10 (6-30) months. found that IgG4 ≥ 6.5g/L (OR 1.52-11.06), IgG 20.8g/L 1.11-7.23), responder index (RI) 9 1.28-11.37), more + plasma cell infiltration (≥ 60 / HPF visceral organs, 200 head neck organs) 1.79-22.41) independent relapse. A score was explored recurrence including three (IgG 20.8g/L, RI ≥9, infiltration). three-year rate no, one, two, risk 0%, 27.3%, 66.7%, 100%, Conclusion: Patients’ earlier 6.5g/L, independently predicted include infiltration), which might be evaluate IgG4-RD. References: [1]DESHPANDE V, ZEN Y, CHAN J K, et al. Consensus statement on pathology IgG4-related disease[J]. Mod Pathol,2012,25(9): 1181-1192. [2]JENNETTE C, FALK R J, BACON P A, 2012 revised International Chapel Hill Conference Nomenclature Vasculitides[J]. Arthritis Rheum,2013,65(1): 1-11. [3]OKAZAKI UMEHARA H. Are Classification Criteria Now Possible? Concept IgG4-Related Disease Proposal Comprehensive Diagnostic Japan[J]. Int Rheumatol,2012,2012: 357071. [4]SHIMOSEGAWA T, CHARI S FRULLONI L, consensus diagnostic criteria autoimmune pancreatitis: guidelines Association Pancreatology[J]. Pancreas,2011,40(3): 352-358. [5]OHARA H, OKAZAKI TSUBOUCHI Clinical sclerosing cholangitis 2012[J]. Hepatobiliary Pancreat Sci,2012,19(5): 536-542. [6]KAWANO M, SAEKI NAKASHIMA kidney Clin Exp Nephrol,2011,15(5): 615-626. [7]GOTO TAKAHIRA AZUMI A. ophthalmic Jpn Ophthalmol,2015,59(1): 1-7. [8]MATSUI S, YAMAMOTO MINAMOTO Proposed respiratory Respir Investig,2016,54(2): 130-132. [9]WEN ZHANG H S. Management Lancet Rheumatol,2019,1: e55-e65. [10]EBBO DANIEL PAVIC systemic disease: features treatment response French cohort: results multicenter registry[J]. Medicine (Baltimore),2012,91(1): 49-56. Disclosure Interests: None declared